Evercore ISI analyst Vijay Kumar raised the firm’s price target on Danaher to $278 from $275 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher initiated with an Overweight at Stephens
- Danaher put volume heavy and directionally bearish
- Danaher backs FY24 revenue growth down in low-single digits from $23.89B in FY23
- Danaher still sees Q3 non-GAAP revenue down in low-single digits year-over-year
- Wells Fargo sees more downside than upside, starts Danaher with Equal Weight